Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7790121 induction therapy study in moderately to severely active Crohn's disease
ChiCTR2500098418Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing RO7790121 group with Placebo group (2 arms). Primary endpoints: Clinical remission at Week 12 and Endoscopic response at Week 12. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2500098418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098418.